ICAM1 and thyroid cancer: Sparing toxicities by reducing the affinity has been demonstrated for ICAM-1 specific CAR T cells (micromolar affinity) in thyroid cancer (173), as well as in HER2- and EGFR-specific CAR T cells in various solid cancer models including ovarian and prostate (174).